{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:32Z","timestamp":1761856052118,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.medcli.2019.03.011","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:38:08Z","timestamp":1558607888000},"page":"83-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiencia cl\u00ednica con tolvapt\u00e1n en pacientes con poliquistosis renal"],"prefix":"10.1016","volume":"155","author":[{"given":"Covadonga","family":"L\u00f3pez del Moral Cuesta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Fern\u00e1ndez Fresnedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mart\u00edn Penagos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Poliquistosis renal autos\u00f3mica dominante: Gu\u00edas cl\u00ednicas espa\u00f1olas de poliquistosis renal autos\u00f3mica dominante","year":"2017","author":"Ars","key":"10.1016\/j.medcli.2019.03.011_bib0030"},{"key":"10.1016\/j.medcli.2019.03.011_bib0035","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","article-title":"Estimating prevalence in single-gene kidney diseases progressing to renal failure","volume":"58","author":"Levy","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2019.03.011_bib0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2019.03.011_bib0045","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2019.03.011_bib0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319302143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319302143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:50:56Z","timestamp":1758419456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319302143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0025775319302143"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.03.011","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experiencia cl\u00ednica con tolvapt\u00e1n en pacientes con poliquistosis renal","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}